

<b>AGENDA</b>	
<b>11:00 AM – 11:10 AM</b> <i>(10 min)</i>	<b>Welcome and opening remarks</b> Vishal Bhatnagar – Medical Oncologist, FDA Paul Kluetz – Medical Oncologist, FDA
<b>11:10 AM – 12:25 PM</b> <i>(1 hr. 15 min)</i>	<b>Session 1: Revisiting Core Item Sets in Oncology Trials – Where are we and where do we want to go?</b> Moderator: Terri Armstrong - Outcomes Researcher, NCI
<b>Panelists:</b> <ul style="list-style-type: none"> <li>• Yelak Biru – Patient Advocate, International Myeloma Foundation</li> <li>• Erica Horodniceanu – Senior Health Scientist, FDA</li> <li>• Tito Mendoza – Senior Scientist, NCI</li> <li>• Bryce Reeve – Professor, Duke University School of Medicine</li> <li>• Gita Thanarajasingam – Lymphoma Hematologist, Mayo Clinic</li> <li>• Lynne Wagner – Professor, University of North Carolina</li> </ul> <b>Objectives:</b> <ol style="list-style-type: none"> <li>1. <i>Provide contextual background for patient-reported symptom assessment – an overview of existing “core” symptom sets.</i></li> <li>2. <i>Review how current clinical trials require novel methods to select symptoms, including use of PRO item libraries.</i></li> <li>3. <i>Emphasize how early phase trials, pediatric trials, and use of novel agents require parsimonious symptom assessment.</i></li> </ol>	
<b>12:25 PM – 12:40 PM</b> <i>(15 min)</i>	<b>Break</b>
<b>12:40 PM – 1:55 PM</b> <i>(1 hr 15 min)</i>	<b>Session 2: Revisiting Core Item Sets in Oncology Trials – How do we get there?</b> Moderator: Vishal Bhatnagar – Medical Oncologist, FDA
<b>Panelists:</b> <ul style="list-style-type: none"> <li>• Ethan Basch – Professor and Chief of Oncology, University of North Carolina</li> <li>• Cheryl Coon – Vice President, Clinical Outcome Assessment Program, Critical Path Institute</li> <li>• Amylou Dueck – Biostatistician, Mayo Clinic</li> <li>• Megan Fitter – Clinical Outcomes Assessment Reviewer, FDA</li> <li>• Jan Geissler – Patient Advocate, Patvocates</li> <li>• Madeline Pe – Head of the Quality-of-Life Department, EORTC</li> <li>• Ashley Wilder Smith – Chief, Outcomes Research Branch, NCI</li> </ul> <b>Objectives:</b> <ol style="list-style-type: none"> <li>1. <i>Consider actionable methods to modernize existing PRO item libraries.</i></li> <li>2. <i>Discuss a framework for selecting treatment-related symptoms across many therapeutic contexts.</i></li> <li>3. <i>Review analysis and visualization techniques for treatment related symptoms assessed during cancer trials.</i></li> </ol>	
<b>1:55 PM – 2:25 PM</b> <i>(30 min)</i>	<b>Panel Discussion Q &amp; A</b> Moderator: Vishal Bhatnagar – Medical Oncologist, FDA
<b>Panelists:</b> All available panelists from Sessions 1 & 2	
<b>2:25 PM – 2:30 PM</b> <i>(5 min)</i>	<b>Workshop conclusion and adjournment</b> Paul Kluetz - Medical Oncologist, FDA Terri Armstrong – Outcomes Researcher, NCI Vishal Bhatnagar – Medical Oncologist, FDA